Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | Help us explore the reuse opportunities for data and samples in clinical and biological cancer research.
Our data and samples reuse special interest group is running a survey to help us understand how you’re currently using data and samples in your research and what challenges you’re encountering.
We’ll use this information to build on the support we provide to researchers so that they can maximise the use of data for patient benefit.
|
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
| | Cancer Grand Challenges
Team eDyNAmiC published three papers on ecDNA back-to-back in Nature |
|
Paul Mischel, Howard Chang, Mariam Jamal-Hanjani of Cancer Grand Challenges team eDyNAmiC and their international collaborators have revealed insights into the mechanisms and therapeutic potential of extrachromosomal DNA (ecDNA).
The team analysed the genomes from nearly 15,000 patients from the Genomics England Cohort, in work co-led by collaborator Charlie Swanton, across 39 different tumour types, the largest single collection of whole-genome sequenced cancer patient samples available. They have shown the prevalence of ecDNA in samples associated with tumour stage, treatment, metastases, decreased survival and immune evasion.
Publishing three back-to-back papers in Nature and landing ecDNA on the cover, eDyNAmiC are rapidly advancing our understanding of ecDNA.
Take a deeper dive into eDyNAmiC's journey so far, going all the way from fundamental mechanisms through to identifying an actionable target that's already being tested in the clinic.
Team eDyNAmiC is funded by us and the National Cancer Institute through Cancer Grand Challenges.
|
| | |
|
|
|
|
|
| | | | | | The paper demonstrates the remarkable diversity and cooperative mechanism of ecDNA elements across cancer.
It shows how ecDNA drives tumour growth signals through high copy number oncogene amplification, how it alters transcriptional landscapes and how it may suppress the immune system. | | |
|
|---|
| | | | | | | The team discovered that inheritance of ecDNAs which cooperate to boost oncogene expression can actually be collaboratively segregated, suggesting unique therapeutic opportunities via indirect targeting of oncogenes. | | |
|
|---|
| | | | | | | Results revealed that the transcriptional advantage of ecDNA in cancer can be turned against itself. The conflict between RNA transcription and DNA replication can be enhanced by inhibiting CHK1, causing ecDNA-containing tumour cells to self-destruct. | | |
|
|---|
|
|
|
|
Cancer Grand Challenges Conference: extrachromosomal DNA |
| Interested in more conversations around ecDNA? Join the first edition of the Cancer Grand Challenges Conference Series in London in June 2025. Hear from Paul, Howard, Mariam and a stellar line-up of researchers across diverse backgrounds on emerging concepts, open questions and the future for this field. |
| | |
|
|
|
Webinar: Preparing your data for reuse |
| Tune in for the next session in our data webinar series on 22 January 12-1pm to learn more from Joe Day (Cancer Research Horizons) about how researchers can prepare their data from the start to maximise the possibility of reuse, including in commercial collaborations. Joe will also share more about the support we offer to help facilitate this.
Maximise the impact of data and research by joining us and asking your questions.
|
| | |
|
|
|
Join the Seminar on Novel Approaches to Treating Prostate Cancer |
| Oglesby Cancer Research Centre will host a hybrid session on 21 November where Adam Sharp (The Institute of Cancer Research and Royal Marsden NHS Foundation Trust), will share insights on “Targeting the Intrinsic Apoptosis Pathway in Lethal Prostate Cancer.”
This talk will dive into innovative approaches aiming to counter treatment resistance and improve patient outcomes.
Tea and coffee will be available from 09:45, with the seminar starting at 10:00. Spaces are limited, so register soon to secure your spot. |
| | |
|
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
